Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Licenses Technology From RiboTask

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDRNA today said it has acquired the exclusive rights to develop, make, use, and sell unlocked nucleobase analog-based diagnostics from RiboTask.

The agreement expands a previous agreement between the two firms for exclusive rights to develop UsiRNA-based therapeutics. As a result of today's announcement and previously obtained exclusive rights to conformationally restricted nucleotide technology for both therapeutics and diagnostics, MDRNA now has one of the few intellectual property portfolios that support a nucleic acid-based personalized medicine platform and the ability to pursue proprietary nucleic acid-based therapeutics and diagnostics, the Bothell, Wash., firm said in a statement.

Ribotask, a privately owned Danish firm, which develops and synthesizes RNA chemistries, keeps co-exclusive right to manufacture, sell, and sublicense UNA technology for reagents development.

Financial terms of the deal were not disclosed.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.